Sees FY24 System-wide comparable RevPAR, on a currency neutral basis up 2.0%-2.5% vs. last year. Sees FY24 Adjusted EBITDA $3.375B-$3.405B and contract acquisition costs and capital expenditures, excluding amounts reimbursed by third parties, $200M-$250M.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLT: